D&D Pharmatech’s liver drug resolves MASH in 62.5% of patients
D&D Pharmatech reports 48-week biopsy data for zabopegdutide, a GLP-1-based drug, and says licensing talks with big pharma are underway. Nobody enjoys a liver biopsy, which involves a needle and a sliver of tissue that a pathologist then studies under a microscope. It is still the final word on

<p>D&D Pharmatech reports 48-week biopsy data for zabopegdutide, a GLP-1-based drug, and says licensing talks with big pharma are underway. Nobody enjoys a liver biopsy, which involves a needle and a sliver of tissue that a pathologist then studies under a microscope. It is still the final word on </p>